Unlearn
Trace will use Unlearn's digital twin generator for ALS to create digital twins of clinical trial participants to advance ALS research.
The California-based company will put the funds toward its workforce, growing its data and further investing in R&D initiatives and engineering capabilities.
Also: RPM company Blue Spark Technologies brought in $40 million in IP-backed debt financing, and Click Therapeutics secured a $15 million loan.
With the creation of digital twins in studies, Unlearn generates an intelligent control arm that can reduce the sample size and decrease the number of participants given the placebo.